ProFibrix Secures Funding for Progression of Lead Product Into Late Stage Clinical Development and Announces Management and Supervisory Board Appointments

Leiden, The Netherlands and Seattle (ots/PRNewswire) -
ProFibrix B.V., a leader in the development of innovative products
that help stop bleeding (hemostasis) after surgery, today announced
the successful closing of a series B follow-on financing. In
conjunction with the financing and to support the company's next
stage of development towards commercialization, ProFibrix also
announced several management and Supervisory Board appointments.

The Supervisory Board will be chaired by independent director
Leonard Kruimer, Chief Financial Officer of Crucell. Over the past
decade, Mr. Kruimer has been instrumental in building Crucell from an
entrepreneurial start-up into a global vaccine company, taking the
company public and leading a number of large and successful M&A
transactions. Also joining the Supervisory Board as an independent
director is Vic Schmitt. Mr. Schmitt has been a long-time senior
executive at Baxter International, a key player in the hemostasis
market, where he last served as President of Venture Management.

In addition to these high profile appointments to the Supervisory
Board, Jan Ohrstrom, has been named Chief Executive Officer. Before
joining ProFibrix, Dr. Ohrstrom was a senior executive at
ZymoGenetics, where he was responsible for the development of several
products, and a member of the team that took the company public. Dr.
Ohrstrom started his career at Novo Nordisk. Jaap Koopman, founding
CEO of ProFibrix, will become Chief Scientific Officer.

In addition to the private funding the company was awarded a
government credit, bringing the total new funds available to the
company for the progression of Fibrocaps(TM) to EUR 15 million (USD
22 million). New investors Vesalius Biocapital and INKEF Capital
co-led the financing round, while existing investors Index Ventures
and Gilde Healthcare Partners also participated. Alain Parthoens from
Vesalius Biocapital, Dirk Kersten from Gilde Healthcare Partners, and
Francesco De Rubertis from Index Ventures will also hold seats on the
board of ProFibrix.

The proceeds of the financing will be used to progress the
company's lead product Fibrocaps into late stage clinical
development, as well as to support the company's other pipeline
programs. Fibrocaps is currently being investigated in a prospective,
multi-center Phase II study in multiple surgical indications at up to
20 sites, including major U.S. and Dutch academic medical centers. If
this study confirms the positive results of the first Phase II trial,
ProFibrix anticipates initiating a pivotal Phase III trial in early
2012, and file for approval by the U.S. Food and Drug Administration
in early 2013.

Jan Ohrstrom, MD, said: "We are very pleased to welcome Vesalius
Biocapital and INKEF Capital to our investor base. Our successful
financing and strengthened Supervisory Board and leadership team
should put ProFibrix in an excellent position to continue the
development of Fibrocaps and prepare for its commercial launch. We
would like to extend our gratitude to the parting board members for
their contribution and commitment to the early development of
ProFibrix."

Jaap Koopman said: "Jan Ohrstrom has played a key role in
transitioning ProFibrix to a market-focused company. He has the
capabilities and skills to take ProFibrix through its next stages of
growth to become a leading hemostasis company. I look forward to
seconding him in his new role as CEO, and to continue to contribute
to the development of new products based on our fibrinogen technology
platform."

About Fibrocaps

Fibrocaps is based on a mixture of two essential blood clotting
proteins, fibrinogen and thrombin, and is a unique dry powder topical
tissue sealant that rapidly stops bleeding after or during surgery.
Fibrocaps has major advantages over existing liquid tissue sealants:
it is ready for immediate use, is stable at room temperature, highly
effective and fast acting.

About ProFibrix

ProFibrix (http://www.ProFibrix.com) was founded in 2004 and is
headquartered in Leiden, The Netherlands, with a subsidiary in
Seattle, WA, USA. The company leverages its expertise in fibrinogen
technology to develop and market innovative products for the
hemostasis and regenerative medicine markets. Human fibrinogen plays
a pivotal role in blood clotting and tissue healing. ProFibrix is led
by a team with extensive commercial, clinical and scientific
experience in the hemostasis field.

About Vesalius Biocapital

Vesalius focuses on the creation, financing and growth of
early-stage life science companies. The managed Vesalius funds invest
in areas with a high unmet medical need and a significant profit
potential: new therapeutics, cutting-edge medical devices, innovative
drug delivery technologies and diagnostic tests and instruments with
a high utility level. The expertise of the team ranges from extensive
investment and exit experience to corporate governance, operational
experience, business development, research & development, and IP
management in start-ups and mature life science companies.
Furthermore, individual team members have in-depth technical insights
and competitive scouting experience in the life science sector. For
more information, please visit http://www.vesaliusbiocapital.com.

About INKEF Capital

INKEF Capital, founded in 2010 to create a new way of investing
in start-ups, is an international alliance of two major pension
funds, ABP from the Netherlands, and Canadian pension plan OMERS.
INKEF Capital is investing in the knowledge economy of the future.
The fund will invest from an early stage, and can continue to provide
financing to successful investee companies all the way to a sale or
an IPO. The fund's long term investment strategy is to achieve top
quartile returns consistent with the risk profile of the investment
class. For more information, please visit http://www.inkefcapital.com

About Index Ventures

Index Ventures is a leading pan-European venture capital firm
dedicated to working with entrepreneurs who have the drive and
ability to build world-class technology and life science companies.
The Index Ventures team, which began investing in 1992, has a deep
technology and scientific focus and the ability to leverage a network
of cross-Atlantic strategic relationships. Index proactively seeks
out the top entrepreneurial teams in each investment area and
leverages its core assets in helping the entrepreneurs build their
companies into global leaders. Index Ventures investors include
leading technology firms and institutional investors. Previous
investments include Pangenetics, Genmab, Aegerion, SGX
Pharmaceuticals, Inc., ParAllele Bioscience and Molecular Partners.
For more information, please visit http://www.indexventures.com.

About Gilde Healthcare Partners

Netherlands-based Gilde Healthcare Partners is a transatlantic
venture and growth capital firm focused on private healthcare
technologies and services. It has over EUR400 million under
management and is actively looking to lead new investments in
therapeutics, diagnostics, medical devices and services. Gilde
successfully builds healthcare businesses across Europe and US,
investing up to EUR15 million in a single portfolio company. By
investing in companies with clear, achievable business models, Gilde
has used its financial resources and network to create significant
value for both its investors and the entrepreneurs it backs. For a
list of Gilde's portfolio companies please visit the website at
http://www.gildehealthcare.nl.

ots Originaltext: ProFibrix B.V.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further enquiries: Jan Ohrstrom, MD, CEO,
ProFibrix,+1-206-9105-404, +31-63-1774-620, j.ohrstrom@profibrix.com.
Hans Herklots,Principal, Capricorn One, +41-79-598-7149,
capricorn1@bluewin.ch